T-Cell Therapy Using CD7 Negative T-Cells Expressing CD7 CAR Expressed In Pediatric Patients With Hematological Malignancies.
Key facts
- Who runs it
- St. Jude Children's Research Hospital
- Where
- Memphis, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 32 people, planned
- Starts
- Dec 2026
- Expected to end
- Dec 2034
- Type of study
- Interventional, 2 groups
- Treatments tested
- Fludarabine
- Cyclophosphamide
- CliniMACS
- Mesna
- Record updated
- 17 November 2026
Who can take part
- Age
- Up to 21 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 51 criteriaShow less
Other criteria
- Procurement and T-cell production Eligibility*
- *a previously frozen, autologous leukapheresis product can be used for T-cell production Recipient Inclusion
- Age ≤21 years old
- Relapsed/refractory CD7+ AML; Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR); Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy
- Relapsed/refractory T-cell ALL/lymphoma; Relapsed disease: Patients developing recurrent disease after a prior complete remission (CR); Refractory disease: Patients with persistent disease despite 2 cycles of induction chemotherapy
- Estimated life expectancy of >12 weeks
- Karnofsky or Lansky (age-dependent) performance score ≥50
- Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis
- Patient must have an identified HCT donor
- For females of childbearing age:; Not lactating with intent to breastfeed; Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
- For patients on Arm A: Meets eligibility criteria to undergo autologous apheresis, or have a previously frozen, autologous leukapheresis product that can be used for T-cell production
- For patients on Arm B: Have an available donor that meets donor criteria; Recipient Exclusion
- Known primary immunodeficiency
- Known HIV positivity
- Severe intercurrent bacterial, viral or fungal infection
- History of hypersensitivity to cornstarch or hydroxyethyl starch
- Patients with acute promyelocytic leukemia (APL)
- Known contraindication to protocol defined lymphodepleting chemotherapy regimens of Fludarabine/cyclophosphamide
- AML patients who failed FDA-approved targeted treatment options (e.g., FLT3 inhibitors, IDH1/IDH2 inhibitors, NPM1/KMT2A, CD33-directed.We define therapy failure as meeting one of the following; contraindications to receiving targeted therapy; or; toxicities that necessitate stopping the targeted therapy; or; progressive disease; Donor eligibility criteria for Arm B of the study: Apheresis and manufacturing
- Recipient with relapsed CD7+ disease
- Allogeneic donor either previous transplant donor for recipient, or haplo-identical donor if previous transplant donor is not available or autologous collection is not feasible in patients that have not had a previous transplant
- HIV negative
- For females of child bearing age:
- Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment AND; o Not lactating with intent to breastfeed
- Regarding donation eligibility, is identified as either:; Completed the process of donor eligibility determination as outlined in 21CFR 1271 and agency guidance; OR; Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271; This will follow standard allogeneic donor criteria per FDA mandate as defined in our allogeneic transplant studies Recipient Pre-Treatment Tests Eligibility (Arm B) Inclusion
- Identified eligible study recipient with relapsed and/or refractory CD7-positive hematological malignancy Exclusion
- None; Treatment Eligibility (Arm A and Arm B) Inclusion
- Age ≤21 years old
- Detectable CD7+disease
- Estimated life expectancy of >8 weeks
- Karnofsky or Lansky (age-dependent) performance score ≥ 50
- Patients with a history of prior allogeneic HCT must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion
- Patient must have an identified HCT donor
- Adequate cardiac function defined as left ventricular ejection fraction >40%, or shortening fraction ≥25%
- EKG without evidence of clinically significant arrhythmia
- Adequate renal function defined as creatinine clearance or radioisotope GFR 50 ml/min/1.73m2 (GFR 40 ml/min/1.73m2 if < 2 years of age)
- Adequate pulmonary function defined as forced vital capacity (FVC) ≥50% of predicted value; or pulse oximetry ≥92% on room air if patient is unable to perform pulmonary function testing
- Total Bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤5 times the upper limit of normal for age
- Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
- For females of child bearing age:
- Not lactating with intent to breastfeed; Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment; If sexually active, agreement to use birth control until 3 months after T-cell infusion. Male partners should use a condom
- Available autologous transduced T-cells that has met GMP release criteria; Exclusion
- Known primary immunodeficiency
- History of HIV infection
- Clinically significant active infection including fungal infection with ongoing antifungal therapy, viral infection or uncontrolled viral reactivation of EBV, CMV, Adv, BK-virus, or HHV-6
- Receiving systemic steroids therapy exceeding the equivalent of 0.5 mg/kg/day of methylprednisolone, in the 7 days prior to CD7-CAR T-cell infusion
- Receiving systemic immunosuppressive therapy in the 14 days prior to CD7-CAR T-cell infusion that in the opinion of PI will interfere with the infused product
- Active CNS disease
- Known contraindication to the protocol defined lymphodepleting chemotherapy regimen of fludarabine/ cyclophosphamide
- AML patients who failed FDA-approved targeted treatment options (e.g., FLT3 inhibitors, IDH1/IDH2 inhibitors, NPM1/KMT2A, CD33-directed agents). We define therapy failure as meeting one of the following:; contraindications to receiving targeted therapy; or; toxicities that necessitate stopping the targeted therapy; or; progressive disease
Where in United States
- St. Jude Children's Research HospitalMemphis, United StatesContact: Swati Naik, MBBSNot yet recruiting
About the trial
What the trial wants to find out
Primary Objective:
Read full original descriptionShow less
To determine the safety and maximum tolerated dose of intravenous infusions of escalating doses of CD7 negative T-cells expressing CD7-CARs (CD7-CAR T cells) in pediatric patients with recurrent/refractory CD7+ hematological malignancies after lymphodepleting chemotherapy.
Secondary Objectives:
To evaluate the antileukemic activity of CD7-CAR T cells. As a phase I study, efficacy is not the primary objective of this study, but remains an important outcome to evaluate. We will determine the anti-leukemic activity of the CD7-CAR T cells in the bone marrow and in the treatment of extramedullary disease.
The 2 groups in the trial
- Arm ATreatment being tested
patients will receive autologous CD7-CAR T-cells
Treatment: Fludarabine, Cyclophosphamide, CliniMACS, and Mesna
- Arm BTreatment being tested
Patients will receive lymphodepleting chemotherapy (Cy/Flu), followed by an infusion of CD7-CAR T cells.
Treatment: CliniMACS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 17 November 2026